ArticlePathology research international2012
New Evidence-Based Treatment Approach in Behçet's Disease.
Article in Pathology research international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches.International ophthalmology · 2023Review
- Behçet Disease: An Update for Dermatologists.American journal of clinical dermatology · 2021Review
- Experimental Therapeutic Solutions for Behcet's Disease.Journal of experimental pharmacology · 2021Review
- The possible role of oral microbiome in autoimmunity.International journal of women's dermatology · 2020Review
- Neutrophil elastase and endogenous inhibitors in Behçet's disease saliva.Clinical and experimental immunology · 2020Article
- Sulfasalazine in dermatology: A lesser explored drug with broad therapeutic potential.International journal of women's dermatology · 2020Review
- Review
- Elusive diagnosis of Behcet's disease in setting of painless vision loss.SAGE open medical case reports · 2020Article
- Penicillin in oral aphthosis, new insight for an old drug: A randomized, double-blind, controlled clinical trial.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2020Article
- Lessons of the month 2: A case of Behçet's disease: 70% have ophthalmic involvement.Clinical medicine (London, England) · 2019Article
- Orbital Vasculitides-Differential Diagnosis.Current rheumatology reports · 2019Review
- Concurrent presence of buccal mucosal and ophthalmologic lesions in Behcet's syndrome.Caspian journal of internal medicine · 2018Article
- A case of Behcet's disease posted for surgery: Anaesthetic implications.Indian journal of anaesthesia · 2015Article
- Thrombosis in vasculitis: from pathogenesis to treatment.Thrombosis journal · 2015Article
- Evidence-based practice in Behçet's disease: identifying areas of unmet need for 2014.Orphanet journal of rare diseases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet's disease (BD) is a chronic, relapsing, and debilitating systemic vasculitis of unknown aetiology with the clinical features of mucocutaneous lesions, ocular, vascular, articular, neurologic, gastrointestinal, urogenital, and pulmonary involvement. The disease is much more frequent along the ancient "Silk Route" extending from Eastern Asia to the Mediterranean basin, compared with Western countries. The disease usually starts around the third or fourth decade of life. Male sex and a younger age of onset are associated with more severe disease. Although the treatment has become much more effective in recent years, BD is still associated with severe morbidity and considerable mortality. The main aim of the treatment should be the prevention of irreversible organ damage. Therefore, close monitoring, early, and appropriate treatment is mandatory to reduce morbidity and mortality. The treatment is mainly based on the suppression of inflammatory attacks of the disease using immunomodulatory and immunosuppressive agents. In this paper, current state of knowledge regarding the therapeutic approaches is outlined. To provide a rational framework for selecting the appropriate therapy along the various treatment choices, a stepwise, symptom-based, evidence-based algorithmic approach was developed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.